Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

被引:269
作者
Berger, C
Flowers, ME
Warren, EH
Riddell, SR
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Seattle, WA 98195 USA
关键词
D O I
10.1182/blood-2005-08-3503
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The introduction of an inducible suicide gene such as the herpes simplex virus thymidine kinase (HSV-TK) might allow exploitation of the antitumor activity of donor T cells after allogeneic hematopoietic cell transplantation (HCT) without graft versus host disease. However, HSV-TK is foreign, and immune responses to gene-modified T cells could lead to their premature elimination. We show that after the infusion of HSV-TK-modified donor T cells to HCT recipients, CID8(+) and CD4(+) T-cell responses to HSV-TK are rapidly induced and coincide with the disappearance of transferred cells. Cytokine flow cytometry using an overlapping panel of HSV-TK peptides allowed rapid detection and cluantitation of HSV-TK-specific T cells in the blood and identified multiple immunogenic epitopes. Repeated infusion of modified T cells boosted the induced HSV-TK-specific T cells, which persisted as memory cells. These studies demonstrate the need for nonimmunogenic suicide genes and identify a strategy for detection of CD4(+) and CD8(+) T-cell responses to transgene products that should be generally applicable to monitoring patients on gene therapy trials. The potency of gene-modified T cells to elicit robust and durable immune responses imply this approach might be used for vaccination to elicit T-cell responses to viral or tumor antigens.
引用
收藏
页码:2294 / 2302
页数:9
相关论文
共 56 条
[21]   THYMIDINE KINASE OBLITERATION - CREATION OF TRANSGENIC MICE WITH CONTROLLED IMMUNE-DEFICIENCY [J].
HEYMAN, RA ;
BORRELLI, E ;
LESLEY, J ;
ANDERSON, D ;
RICHMAN, DD ;
BAIRD, SM ;
HYMAN, R ;
EVANS, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) :2698-2702
[22]  
HIGANO CS, 1992, BLOOD, V80, P1437
[23]   Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation [J].
Higano, CS ;
Chielens, D ;
Raskind, W ;
Bryant, E ;
Flowers, MED ;
Radich, J ;
Clift, R ;
Appelbaum, F .
BLOOD, 1997, 90 (07) :2549-2554
[24]  
HOROWITZ MM, 1990, BLOOD, V75, P555
[25]   Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies [J].
Introna, M ;
Barbui, AM ;
Bambacioni, F ;
Casati, C ;
Gaipa, G ;
Borleri, G ;
Bernasconi, S ;
Barbui, T ;
Golay, J ;
Biondi, A ;
Rambaldi, A .
HUMAN GENE THERAPY, 2000, 11 (04) :611-620
[26]   Inhibition of death receptor signals by cellular FLIP [J].
Irmler, M ;
Thome, M ;
Hahne, M ;
Schneider, P ;
Hofmann, B ;
Steiner, V ;
Bodmer, JL ;
Schroter, M ;
Burns, K ;
Mattmann, C ;
Rimoldi, D ;
French, LE ;
Tschopp, J .
NATURE, 1997, 388 (6638) :190-195
[27]   Graft-versus-leukemia reactions in allogeneic chimeras [J].
Kolb, HJ ;
Schmid, C ;
Barrett, AJ ;
Schendel, DJ .
BLOOD, 2004, 103 (03) :767-776
[28]   GRAFT-VERSUS-LEUKEMIA EFFECT OF DONOR LYMPHOCYTE TRANSFUSIONS IN MARROW GRAFTED PATIENTS [J].
KOLB, HJ ;
SCHATTENBERG, A ;
GOLDMAN, JM ;
HERTENSTEIN, B ;
JACOBSEN, N ;
ARCESE, W ;
LJUNGMAN, P ;
FERRANT, A ;
VERDONCK, L ;
NIEDERWIESER, D ;
VANRHEE, F ;
MITTERMUELLER, J ;
DEWITTE, T ;
HOLLER, E ;
ANSARI, H .
BLOOD, 1995, 86 (05) :2041-2050
[29]  
Kornblau SM, 2001, CANCER RES, V61, P3355
[30]   Suicide genes: past, present and future perspectives [J].
Lal, S ;
Lauer, UM ;
Niethammer, D ;
Beck, JF ;
Schlegel, PG .
IMMUNOLOGY TODAY, 2000, 21 (01) :48-54